Breast cancer manifested by hematologic disorders.

  title={Breast cancer manifested by hematologic disorders.},
  author={Takashi Ishikawa and Daisuke Shimizu and Ayako Kito and Ikuko Ota and Takeshi Sasaki and Mikiko Tanabe and Akimitsu Yamada and Hitoshi Arioka and Satoru Shimizu and Junichi Wakasugi and Ryutaro Mori and Takashi Chishima and Yasushi Ichikawa and Itaru Endo},
  journal={Journal of thoracic disease},
  volume={4 6},
Breast cancer is the most common type of cancer in women. However, it is very rarely manifested as hematologic disorders. A 35-year-old woman was admitted because of disseminated intravascular coagulation. Examinations revealed the presence of breast cancer in her left breast; therefore, paclitaxel was administered weekly. Although disseminated intravascular coagulation was controlled, pulmonary dysfunction due to lymphangitis carcinomatosa suddenly occurred 10 weeks after treatment. Pulmonary… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 14 extracted citations

Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2018

PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu • 2014
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 10 references

The basics of epithelial-mesenchymal transition.

The Journal of clinical investigation • 2009
View 1 Excerpt

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Proceedings of the National Academy of Sciences of the United States of America • 2008
View 1 Excerpt

Skeletal metastases.

Clinical orthopaedics and related research • 1986
View 1 Excerpt

Similar Papers

Loading similar papers…